[8-K] Dyadic International, Inc. Reports Material Event
Dyadic International (Nasdaq: DYAI) filed a Form 8-K on 23 Jul 2025 under Item 7.01 (Reg FD) to furnish an investor presentation titled “Precision engineered recombinant protein production that redefines performance, scalability and economy.” The deck, posted on the company’s website and attached as Exhibit 99.1, outlines a strategic shift from research-driven to commercially focused operations. Management plans to monetize its patented C1 and Dapibus™ gene-expression platforms by supplying high-value, non-therapeutic proteins to the life-science, food, nutrition and industrial bioprocessing markets. No new financial results, guidance, or transactional details were disclosed. Because the material is “furnished” rather than “filed,” it is not subject to Section 18 liability and will not be automatically incorporated into future Securities Act or Exchange Act filings. Exhibit 104 contains the inline XBRL cover page data.
Dyadic International (Nasdaq: DYAI) ha presentato un Modulo 8-K il 23 luglio 2025, ai sensi della voce 7.01 (Reg FD), per fornire una presentazione agli investitori intitolata “Produzione di proteine ricombinanti di precisione che ridefinisce prestazioni, scalabilità ed economia.” La presentazione, pubblicata sul sito web dell’azienda e allegata come Allegato 99.1, illustra un cambiamento strategico da operazioni orientate alla ricerca a operazioni focalizzate sul commerciale. Il management intende monetizzare le sue piattaforme brevettate di espressione genica C1 e Dapibus™ fornendo proteine non terapeutiche ad alto valore ai mercati delle scienze della vita, alimentare, nutrizione e bioprocessi industriali. Non sono stati divulgati nuovi risultati finanziari, previsioni o dettagli transazionali. Poiché il materiale è “fornito” e non “depositato,” non è soggetto alla responsabilità ai sensi della Sezione 18 e non sarà automaticamente incorporato nelle future dichiarazioni ai sensi del Securities Act o dell’Exchange Act. L’Allegato 104 contiene i dati della pagina di copertina XBRL inline.
Dyadic International (Nasdaq: DYAI) presentó un Formulario 8-K el 23 de julio de 2025 bajo el ítem 7.01 (Reg FD) para proporcionar una presentación para inversores titulada “Producción de proteínas recombinantes de precisión que redefine rendimiento, escalabilidad y economía.” La presentación, publicada en el sitio web de la empresa y adjunta como Anexo 99.1, detalla un cambio estratégico de operaciones enfocadas en la investigación a operaciones con enfoque comercial. La dirección planea monetizar sus plataformas patentadas de expresión génica C1 y Dapibus™ suministrando proteínas no terapéuticas de alto valor a los mercados de ciencias de la vida, alimentación, nutrición y bioprocesamiento industrial. No se divulgaron nuevos resultados financieros, pronósticos ni detalles transaccionales. Debido a que el material es “proporcionado” y no “presentado,” no está sujeto a la responsabilidad bajo la Sección 18 y no se incorporará automáticamente en futuras presentaciones bajo la Ley de Valores o la Ley de Intercambio. El Anexo 104 contiene los datos de la portada XBRL en línea.
Dyadic International (나스닥: DYAI)는 2025년 7월 23일 항목 7.01(Reg FD)에 따라 투자자 프레젠테이션 "성능, 확장성 및 경제성을 재정의하는 정밀 설계된 재조합 단백질 생산"을 제공하기 위해 Form 8-K를 제출했습니다. 회사 웹사이트에 게시되고 부속서 99.1로 첨부된 이 자료는 연구 중심에서 상업 중심 운영으로의 전략적 전환을 개략적으로 설명합니다. 경영진은 특허받은 C1 및 Dapibus™ 유전자 발현 플랫폼을 활용하여 생명과학, 식품, 영양 및 산업 생물공정 시장에 고부가가치 비치료용 단백질을 공급하여 수익을 창출할 계획입니다. 새로운 재무 결과, 가이드라인 또는 거래 세부사항은 공개되지 않았습니다. 이 자료는 "제출"이 아닌 "제공"된 것이므로 섹션 18 책임 대상이 아니며 향후 증권법 또는 거래법 제출서류에 자동으로 포함되지 않습니다. 부속서 104에는 인라인 XBRL 표지 데이터가 포함되어 있습니다.
Dyadic International (Nasdaq : DYAI) a déposé un formulaire 8-K le 23 juillet 2025 sous l’article 7.01 (Reg FD) pour fournir une présentation aux investisseurs intitulée « Production de protéines recombinantes de précision qui redéfinit la performance, l’évolutivité et l’économie. » La présentation, publiée sur le site web de la société et jointe en tant qu’Exhibit 99.1, décrit un changement stratégique d’une orientation axée sur la recherche vers une orientation commerciale. La direction prévoit de monétiser ses plateformes d’expression génique brevetées C1 et Dapibus™ en fournissant des protéines non thérapeutiques à haute valeur ajoutée aux marchés des sciences de la vie, de l’alimentation, de la nutrition et du bioprocédé industriel. Aucun nouveau résultat financier, prévision ou détail transactionnel n’a été divulgué. Étant donné que le document est « fourni » et non « déposé », il n’est pas soumis à la responsabilité en vertu de la section 18 et ne sera pas automatiquement intégré dans les futurs dépôts au titre du Securities Act ou de l’Exchange Act. L’Exhibit 104 contient les données de la page de couverture XBRL en ligne.
Dyadic International (Nasdaq: DYAI) reichte am 23. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Reg FD) ein, um eine Investorenpräsentation mit dem Titel „Präzisionsentwickelte rekombinante Proteinproduktion, die Leistung, Skalierbarkeit und Wirtschaftlichkeit neu definiert“ bereitzustellen. Das Deck, das auf der Website des Unternehmens veröffentlicht und als Anlage 99.1 beigefügt ist, skizziert eine strategische Neuausrichtung von forschungsgetriebenen zu kommerziell ausgerichteten Aktivitäten. Das Management plant, seine patentierten C1- und Dapibus™-Genexpressionsplattformen zu monetarisieren, indem es hochwertige, nicht-therapeutische Proteine für die Märkte der Lebenswissenschaften, Lebensmittel, Ernährung und industrielle Bioprozessierung liefert. Es wurden keine neuen Finanzergebnisse, Prognosen oder Transaktionsdetails bekannt gegeben. Da das Material „bereitgestellt“ und nicht „eingereicht“ wurde, unterliegt es nicht der Haftung gemäß Abschnitt 18 und wird nicht automatisch in zukünftige Einreichungen nach dem Securities Act oder Exchange Act aufgenommen. Anlage 104 enthält die Inline-XBRL-Titelseitendaten.
- Strategic pivot to commercialization may unlock new revenue streams across multiple end-markets.
- Emphasis on proprietary C1 and Dapibus™ platforms reinforces technological differentiation.
- No financial metrics, contracts or timelines were provided to gauge revenue impact.
- Information classified as “furnished” limits investor protections and may reduce disclosure rigor.
Insights
TL;DR: Informational 8-K; outlines commercial focus but lacks financial metrics—impact neutral.
The filing merely furnishes an investor deck, so there is no legally binding disclosure of revenues, margins or forecasts. While the move from R&D to commercialization could expand addressable markets and improve cash-flow visibility, the absence of quantified targets or customer agreements prevents valuation adjustments at this stage. Because the information is not “filed,” investors receive limited recourse if projections prove optimistic. I therefore view the event as not immediately price-moving, pending concrete revenue evidence.
TL;DR: Highlighted C1/Dapibus platforms show technical edge; market uptake still unproven.
Dyadic continues to market its fungal C1 and plant-based Dapibus™ expression systems as faster and cheaper than CHO or microbial alternatives. Positioning toward food and industrial enzymes diversifies risk away from competitive therapeutic biologics. However, without announced manufacturing partnerships, regulatory clearances, or pilot-scale data, the commercial roadmap remains theoretical. Overall, the disclosure confirms strategic intent but offers little new operational substance.
Dyadic International (Nasdaq: DYAI) ha presentato un Modulo 8-K il 23 luglio 2025, ai sensi della voce 7.01 (Reg FD), per fornire una presentazione agli investitori intitolata “Produzione di proteine ricombinanti di precisione che ridefinisce prestazioni, scalabilità ed economia.” La presentazione, pubblicata sul sito web dell’azienda e allegata come Allegato 99.1, illustra un cambiamento strategico da operazioni orientate alla ricerca a operazioni focalizzate sul commerciale. Il management intende monetizzare le sue piattaforme brevettate di espressione genica C1 e Dapibus™ fornendo proteine non terapeutiche ad alto valore ai mercati delle scienze della vita, alimentare, nutrizione e bioprocessi industriali. Non sono stati divulgati nuovi risultati finanziari, previsioni o dettagli transazionali. Poiché il materiale è “fornito” e non “depositato,” non è soggetto alla responsabilità ai sensi della Sezione 18 e non sarà automaticamente incorporato nelle future dichiarazioni ai sensi del Securities Act o dell’Exchange Act. L’Allegato 104 contiene i dati della pagina di copertina XBRL inline.
Dyadic International (Nasdaq: DYAI) presentó un Formulario 8-K el 23 de julio de 2025 bajo el ítem 7.01 (Reg FD) para proporcionar una presentación para inversores titulada “Producción de proteínas recombinantes de precisión que redefine rendimiento, escalabilidad y economía.” La presentación, publicada en el sitio web de la empresa y adjunta como Anexo 99.1, detalla un cambio estratégico de operaciones enfocadas en la investigación a operaciones con enfoque comercial. La dirección planea monetizar sus plataformas patentadas de expresión génica C1 y Dapibus™ suministrando proteínas no terapéuticas de alto valor a los mercados de ciencias de la vida, alimentación, nutrición y bioprocesamiento industrial. No se divulgaron nuevos resultados financieros, pronósticos ni detalles transaccionales. Debido a que el material es “proporcionado” y no “presentado,” no está sujeto a la responsabilidad bajo la Sección 18 y no se incorporará automáticamente en futuras presentaciones bajo la Ley de Valores o la Ley de Intercambio. El Anexo 104 contiene los datos de la portada XBRL en línea.
Dyadic International (나스닥: DYAI)는 2025년 7월 23일 항목 7.01(Reg FD)에 따라 투자자 프레젠테이션 "성능, 확장성 및 경제성을 재정의하는 정밀 설계된 재조합 단백질 생산"을 제공하기 위해 Form 8-K를 제출했습니다. 회사 웹사이트에 게시되고 부속서 99.1로 첨부된 이 자료는 연구 중심에서 상업 중심 운영으로의 전략적 전환을 개략적으로 설명합니다. 경영진은 특허받은 C1 및 Dapibus™ 유전자 발현 플랫폼을 활용하여 생명과학, 식품, 영양 및 산업 생물공정 시장에 고부가가치 비치료용 단백질을 공급하여 수익을 창출할 계획입니다. 새로운 재무 결과, 가이드라인 또는 거래 세부사항은 공개되지 않았습니다. 이 자료는 "제출"이 아닌 "제공"된 것이므로 섹션 18 책임 대상이 아니며 향후 증권법 또는 거래법 제출서류에 자동으로 포함되지 않습니다. 부속서 104에는 인라인 XBRL 표지 데이터가 포함되어 있습니다.
Dyadic International (Nasdaq : DYAI) a déposé un formulaire 8-K le 23 juillet 2025 sous l’article 7.01 (Reg FD) pour fournir une présentation aux investisseurs intitulée « Production de protéines recombinantes de précision qui redéfinit la performance, l’évolutivité et l’économie. » La présentation, publiée sur le site web de la société et jointe en tant qu’Exhibit 99.1, décrit un changement stratégique d’une orientation axée sur la recherche vers une orientation commerciale. La direction prévoit de monétiser ses plateformes d’expression génique brevetées C1 et Dapibus™ en fournissant des protéines non thérapeutiques à haute valeur ajoutée aux marchés des sciences de la vie, de l’alimentation, de la nutrition et du bioprocédé industriel. Aucun nouveau résultat financier, prévision ou détail transactionnel n’a été divulgué. Étant donné que le document est « fourni » et non « déposé », il n’est pas soumis à la responsabilité en vertu de la section 18 et ne sera pas automatiquement intégré dans les futurs dépôts au titre du Securities Act ou de l’Exchange Act. L’Exhibit 104 contient les données de la page de couverture XBRL en ligne.
Dyadic International (Nasdaq: DYAI) reichte am 23. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Reg FD) ein, um eine Investorenpräsentation mit dem Titel „Präzisionsentwickelte rekombinante Proteinproduktion, die Leistung, Skalierbarkeit und Wirtschaftlichkeit neu definiert“ bereitzustellen. Das Deck, das auf der Website des Unternehmens veröffentlicht und als Anlage 99.1 beigefügt ist, skizziert eine strategische Neuausrichtung von forschungsgetriebenen zu kommerziell ausgerichteten Aktivitäten. Das Management plant, seine patentierten C1- und Dapibus™-Genexpressionsplattformen zu monetarisieren, indem es hochwertige, nicht-therapeutische Proteine für die Märkte der Lebenswissenschaften, Lebensmittel, Ernährung und industrielle Bioprozessierung liefert. Es wurden keine neuen Finanzergebnisse, Prognosen oder Transaktionsdetails bekannt gegeben. Da das Material „bereitgestellt“ und nicht „eingereicht“ wurde, unterliegt es nicht der Haftung gemäß Abschnitt 18 und wird nicht automatisch in zukünftige Einreichungen nach dem Securities Act oder Exchange Act aufgenommen. Anlage 104 enthält die Inline-XBRL-Titelseitendaten.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices and zip code)
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
On July 23, 2025, Dyadic International, Inc. (“Dyadic” or the “Company”) posted a presentation entitled “Precision engineered recombinant protein production that redefines performance, scalability and economy” on the Company’s website at www.dyadic.com under the “Investors” tab.
The presentation highlights Dyadic’s strategic transition from a research driven organization to a commercially focused enterprise, with an emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus™ gene expression platforms and focus on commercializing high-value, non-therapeutic proteins in the life sciences, food, nutrition and industrial bioprocessing sectors.
Representatives of Dyadic will use the presentation in industry conferences, investor conferences and investor meetings from time to time. A copy of the presentation is also attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is being furnished herein:
| Exhibit Number | Description | |
| 99.1 | Dyadic International Presentation, “Precision engineered recombinant protein production that redefines performance, scalability and economy”, dated July 23 2025 | |
| 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 23, 2025
| Dyadic International, Inc. | ||
| By: | /s/ Ping Rawson | |
| Name: | Ping Rawson | |
| Title: | Chief Financial Officer | |
FAQ
What did Dyadic International (DYAI) disclose in its 8-K dated July 23 2025?
Does the 8-K include updated financial results or guidance for DYAI?
Why is the presentation classified as “furnished” and not “filed”?
What markets does Dyadic plan to target with its C1 and Dapibus™ platforms?
Where can investors access the full Dyadic presentation?
